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Abstract
Background: The mismatch between diffusion weighted imaging (DWI) lesion and perfusion
imaging (PI) deficit volumes has been used as a surrogate of ischemic penumbra. This
pathophysiology-orientated patient selection criterion for acute stroke treatment may have the
potential to replace a fixed time window. Two recent trials - DEFUSE and EPITHET - investigated
the mismatch concept in a multicenter prospective approach. Both studies randomized highly
selected patients (n = 74/n = 100) and therefore confirmation in a large consecutive cohort is
desirable. We here present a single-center approach with a 3T MR tomograph next door to the
stroke unit, serving as a bridge from the ER to the stroke unit to screen all TIA and stroke patients.
Our primary hypothesis is that the prognostic value of the mismatch concept is depending on the
vessel status. Primary endpoint of the study is infarct growth determined by imaging, secondary
endpoints are neurological deficit on day 5-7 and functional outcome after 3 months.
Methods and design: 1000Plus is a prospective, single centre observational study with 1200
patients to be recruited. All patients admitted to the ER with the clinical diagnosis of an acute
cerebrovascular event within 24 hours after symptom onset are screened. Examinations are
performed on day 1, 2 and 5-7 with neurological examination including National Institute of Health
Stroke Scale (NIHSS) scoring and stroke MRI including T2*, DWI, TOF-MRA, FLAIR and PI. PI is
conducted as dynamic susceptibility-enhanced contrast imaging with a fixed dosage of 5 ml 1 M
Gadobutrol. For post-processing of PI, mean transit time (MTT) parametric images are determined
by deconvolution of the arterial input function (AIF) which is automatically identified. Lesion
volumes and mismatch are measured and calculated by using the perfusion mismatch analyzer
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examination and day 5-7 follow up.
Discussions: The aim of this study is to describe the incidence of mismatch and the predictive
value of PI for final lesion size and functional outcome depending on delay of imaging and vascular
recanalization. It is crucial to standardize PI for future randomized clinical trials as for individual
therapeutic decisions and we expect to contribute to this challenging task.
Trial Registration: clinicaltrials.gov NCT00715533
Background
Imaging is a central element of stroke diagnostics in clini-
cal routine and randomized clinical trials. With respect to
the label of alteplase, the only approved drug for acute
ischemic stroke treatment, many clinicians consider CT
the gold standard for stroke imaging during the first 3
hours of ictus. CT is implemented in the clinical workflow
at many centers and allows ruling out hemorrhage easily.
However, its sensitivity for ischemic infarction is 40%
with a negative predictive value of 17% [1] and hence the
accuracy to prevent stroke mimic patients from alteplase
treatment is low. Over the last couple of years it has been
shown, that multiparametric MRI is as sensitive to intrac-
erebral hemorrhage (ICH) as CT in an acute stroke setting
[2,3]. In addition MRI offers complex information about
infarction and perfusion deficits, vessel status and extent
of subacute and chronic lesions, within an examination
lasting less than 15 minutes. Several open case series and
multicenter studies underlined the usefulness of MRI in
an acute setting for therapeutic decisions [4-6]. The mis-
match between diffusion restriction and perfusion deficit
volumes has been interpreted as the surrogate of ischemic
penumbra, showing the tissue at risk of infarction - the
target tissue for therapeutic intervention [7-9]. MRI has
been used to replace a narrow time window for thrombol-
ysis by a pathophysiology orientated patient selection
[10,11].
Recently several studies and interventional trials have
used MRI to assess stroke patients. Parsons et al. demon-
strated the feasibility of expanding the thrombolysis time
window by selecting eligible patients via MRI in an open
case series. The trials investigating the safety and efficacy
of desmoteplase selected patients by MR imaging [7,8].
Only patients presenting with a diffusion-weighted imag-
ing (DWI) lesion volume less than a third of the middle
cerebral artery (MCA) territory and presenting with an
imaging surrogate of penumbra have been randomized.
The 'Desmoteplase In Acute Ischemic Stroke' (DIAS) and
'Dose Escalation of Desmoteplase for Acute Ischemic
Stroke' (DEDAS) trials show a significant correlation
between early reperfusion at 6 hours and clinical outcome
assessed on day 90. There are several possible explana-
tions to the failing proof of the mismatch concept in the
recently published DIAS II trial - a less severe baseline
National Institute of Health Stroke Scale (NIHSS) score,
missing vessel occlusion in a substantial percentage of
cases and an unexpectedly high rate of spontaneous recov-
eries in the placebo group being the most important ones.
Furthermore, Hill pointed out the dependence of the
imaging hypothesis from a proven efficacy of the study
drug [12,13].
Two investigator-initiated trials named 'Diffusion and
Perfusion Imaging Evaluation For Understanding Stroke
Evolution' (DEFUSE) and 'Echoplanar Imaging Thrombo-
lytic Evaluation Trial' (EPITHET) investigated the advan-
tages of MRI in acute stroke [14,15]. Both trials used
alteplase to treat patients and were limited by low recruit-
ing rates. DEFUSE screened 1020 patients for a total enrol-
ment of 74 patients over a period of four years. A
secondary analysis of the DEFUSE population with tech-
nically adequate MR angiographies (MRA) suggests that
recanalization has a significant influence on the reliability
of the mismatch concept [16]. EPITHET had a 7 years
recruiting period. After screening 3908 patients 101 had
been included. These data based on a selected population
are not a sufficient basis to judge the mismatch concept
for a broad population.
Having the opportunity of a 3T MR scanner next door to
the stroke unit and general neurologic ward serving as a
bridge from the emergency ward to a timely thrombolytic
therapy we are enabled to image all stroke and TIA
patients. We will measure the incidence of different imag-
ing patterns and hypothesize that the prognostic value of
mismatch differs based on MRA findings and delay
between the time of onset and MRI examination.
Methods and design
Study Design
"1000Plus" is designed as a prospective, single centre
observational study conducted by the Center for Stroke
Research Berlin at the Campus Benjamin Franklin of the
Charité University Hospital Berlin. The protocol received
approval by the local Ethics Committee (EA4/026/08).
MRI examination is routinely performed even if the
patient is unable to give informed consent due to expectedPage 2 of 8
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aphasic patients. Study entry and storage of data require
subsequent consent by the patient or a legally authorized
representative.
Duration and expected study completion
A screening period of 24 months is scheduled. End of
study will be at the 3 month follow up of the last patient
in. Recruiting has started 1-9-2008. Expected study com-
pletion date 1-12-2010. A further 6 months are planned
for the evaluation of the predefined primary and second-
ary hypotheses.
Patients
1200 Patients are going to be allocated to the trial. We
estimated this inclusion goal on the basis of DEFUSE and
EPITHET interpolated to our wider inclusion criteria
towards TIAs and strokes with a minor deficit. With our
given setting of about 1200 patients with an acute cere-
brovascular event admitted to the emergency ward every
year we expect to exam about 800 patients/year and about
600 of them are expected to give informed consent. An
interims analysis of the first 3 months of inclusion is cur-
rently ongoing. A second analysis after the enrolment of
600 patients is planned. Those analyses will also be used
to confirm the inclusion rates and power estimations. For
a flow chart of study design and patient inclusion see Fig-
ure 1.
Inclusion criteria
1. Patients admitted to the emergency ward with the
clinical diagnosis of an acute cerebrovascular event
within the last 24 hours who match the general MRI
eligibility criteria.
2. Age older than 18 years
Exclusion criteria
1. Pregnancy
2. Contraindications to MRI (i.e. pacemaker)
Methods
A. Stroke MRI
All examinations are performed with a 3T MR scanner
(Tim Trio; Siemens AG, Erlangen, Germany) fully dedi-
cated to clinical research. Our MRI protocol for acute
stroke patients contains the following sequences for the
day of admission (day 1) and day 2: T2*-weighted imag-
ing to screen for ICH; DWI to assess cerebral infarction;
time-of-flight MR-Angiography (TOF MRA) to detect ves-
sel occlusion; Fluid-attenuated inverse recovery (FLAIR)
to estimate microangiopathic lesions load and to investi-
gate the age of the recent lesion; perfusion imaging (PI) to
determine the tissue at risk. On day 5-7 a third measure-
ment with a shorter protocol - without PI - will be per-
formed to assess the final infarct size on FLAIR. PI is being
conducted as dynamic susceptibility-enhanced contrast
imaging. We apply a fixed dosage of 5 ml Gadovist®
(Gadobutrol, 1 M, Bayer Schering Pharma AG, Berlin,
Germany) followed by 20 ml saline by a power injector
(Spectris, Medrad Inc., Warrendale PA, USA) both at a rate
of 5 ml/s. Patients weighing ≥100 kg or ≤50 kg receive 6
ml or 4 ml contrast agent respectively. For sequence
parameters see Table 1.
For post-processing of PI, mean transit time (MTT) para-
metric images are determined by deconvolution of the
arterial input function (AIF) for which multiple voxels are
automatically identified. MTT maps are generated after
sSVD (standard singular value decomposition) and bSVD
(block-circulant SVD) deconvolution with the Perfusion
Mismatch Analyzer software (PMA). Therefore, we will be
able to compare a non-delay-corrected (sSVD) to a delay-
corrected (bSVD) approach. If the interim analysis
presents a significant superiority of one post-processing
method over the other, all further data will be processed
in that manner. Raters semi-automatically define a region
of interest (ROI) in DWI, PI-maps and FLAIR images to
measure infarct and perfusion deficit volumes. Volumes
and mismatch are then calculated by using the PMA soft-
ware from the Acute Stroke Imaging Standardization
Group (ASIST) Japan (Version 3.1 or later).
B. Scales
The NIHSS is a validated instrument used in many clinical
trials to assess the neurologic deficit of stroke patients in a
structured quick way. It has several items testing the sub-
jects' consciousness, limb movement, sensorium, speech,
vision and eye movements. NIHSS score is assessed on
admission (day 1), day 2 and day 5-7 immediately before
imaging. The modified Rankin Scale (mRS) is used to
assess functional recovery in randomized stroke trials. In
this study, mRS is rated 90 days after onset of symptoms
to quantify handicap before and after the event. Demo-
graphic data and course of symptoms are documented
according to the German Stroke database registry guide-
lines as well as stroke subtype and etiology. Delays
between onset, arrival and imaging and duration of hos-
pitalization are recorded.
C. Outcome
The primary endpoint of 1000Plus is the change of infarct
size between the baseline examination and the day 5-7
follow up. Baseline diffusion lesion and perfusion deficit
volumes will be calculated by using the PMA software
from ASIST-Japan. Comparison to the final lesion size on
FLAIR at day 5-7 will be made. Secondary endpoints are
clinical deficit on day 5-7 and functional recovery on day
90 according to NIHSS and mRS score respectively.Page 3 of 8
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The mismatch between DWI and perfusion imaging is a
surrogate of the ischemic penumbra. We hypothesize that
the prognostic value differs depending on recanalization
as shown by MRA on day 2. Furthermore we propose it
declines with increasing delay between time of symptom
onset and MR examination.
Dichotomization
We will dichotomize results based on whether there was
an initial vessel occlusion or not and whether an initially
obstructed vessel was recanalized at day 2 as shown on
MRA. Comparison will be made between the groups
regarding the predictive value of PI. We expect an accurate
prediction of infarct size by DWI if a vessel occlusion is
recanalized on day 2 and an accurate prediction by PI if
the occlusion persists.
Time Stratification
We will group patients according to their delay between
symptom onset and MR imaging time. Predefined time
frames are ≤1 hour, 1-3 hours, 3-9 hours, 9-12 hours and
12-24 hours. We expect better positive and negative pre-




ER & Overnight admissions 
Does patient meet inclusion criteria? CT
Day 2 Stroke MRI  
Hospital discharge 
Day 90 Follow Up via Telephone + mRS 
Inclusion criteria 
MRI eligibility (i.e. no pacemaker)         
>18 years      
<24 h since onset               
informed consent (not necessary for day 1)
Day 5-7 Stroke MRI 
(protocol without PI) 
Stroke MRI 
T2*, DWI, TOF-MRA, FLAIR,PI 
Admission to Stroke Unit or Neurologic Ward 
Treatment according to guidelines – iv. Alteplase
no
yes Page 4 of 8
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In order to evaluate whether there is selection bias in the
study cohort, we will compare demographic values such
as age and baseline stroke severity, etiology and subtype
with all patients admitted to the hospital over the same
time period that were not allocated to the study.
Stroke subtype and etiology
Mulivariate analyses will be used to look for changes in
positive predictive values and accuracy of the model in
different etiologies and subtypes.
Discussion
The primary hypothesis of 1000Plus is that the prognostic
value of PI is crucially depending on the vessel status. We
expect DWI-PI-mismatch to be a more accurate parameter
for treatment decisions if a vessel occlusion, the eventual
target for thrombolysis, is apparent. We hypothesize that
perfusion deficits in patients with patent vessels do not
predict infarction.
Selection
The aim of the study design was to include as many
patients with cerebral ischemia as possible. Therefore we
decided to keep inclusion and exclusion criteria as open as
possible to avoid inclusion bias and production of unrep-
resentative data and chose to include transient ischemic
attacks and strokes with a minor neurological deficit as
well. The maximum delay between time of symptom
onset and imaging was set to 24 hours since perfusion def-
icit declines as delay increases [17]. DEFUSE tested the
hypothesis that mismatch patients have a better outcome
after early reperfusion as opposed to mismatch patients
without early reperfusion and non-mismatch patients.
Only patients who could receive alteplase within 6 hours
from stroke onset were included [14]. EPITHET tested the
hypothesis that alteplase attenuates infarct growth in mis-
match patients. Mismatch was not an inclusion criterion,
whereas inclusion within 3-6 hours after onset was. EPI-
THET was underpowered to prove its primary hypothesis
[15]. Our selection criteria accept patients with a smaller
impairment and a longer time from onset to imaging but
will still provide us with the possibility of comparison via
stratification. Patients with a small impairment were pre-
viously underrepresented in studies investigating the mis-
match model. Especially those patients could benefit from
mismatch-guided thrombolysis and avoidance of the "to-
good-to-treat" concept. Contrary to DEFUSE and EPI-
THET we chose not to screen patients via CT to keep door-
to-MRI times shorter. The inclusion rate is significantly
higher in 1000Plus than in both studies. See Table 2 for a
comparative synopsis of 1000Plus, DEFUSE and EPI-
THET.
MRI Protocol
Imaging at 3T enables to choose a higher resolution,
shorter times of examination or a combination of both
[18,19]. Using both approaches a high spatial resolution
Table 1: MRI protocol parameters in detail
T2*WI DWI 3D TOF-MRA FLAIR PWI
TR, ms 620.0 7600 22.0 8000 1390
TE, ms 20.0 93.0 3.86 100 29.0
b, s/mm2 - 0 (b0) - - -
1000 (b1)
Flip angle 20° - 18° 130° 60°
Averages 1 2 1 1 1 each 1.3-1.5 s
FOV, mm 220 230 200 220 230
Matrix 256 × 192 192 × 192 384 × 268 256 × 256 128 × 128
Thickness, mm 5.0 2.5 0.65 5.0 5
Gap, mm 0.5 0.0 -7,2 0.5 0.5
Slices, n 25 50 25 21 each 1.3-1.5 s
Duration (mm:ss) 01:13 02:11 03:50 01:54 01:58Page 5 of 8
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resolution for perfusion imaging can improve the clinical
utility of a stroke MRI protocol. An examination lasting
less than 15 minutes enables to detect infarction, exclude
hemorrhage, show chronic lesions, and characterize the
vessel status and the size of a perfusion deficit. Having a
purely research dedicated 3T scanner next door to our
stroke unit is a unique condition for clinical stroke
research. This vicinity helps us to design longitudinal
studies with short intervals between MRI scans. As an
example patients are included into a substudy to docu-
ment the time of lesion conversion on FLAIR images with
5 examinations on day of admission. Furthermore we are
evaluating data sets of patients who underwent TOF as
well as contrast agent high resolution MR angiography.
The exclusion of ICH is crucial to perform thrombolytic
therapy. There is still a traditional resistance against using
MRI to detect haemorrhages, but MRI and CT are equiva-
lently validated instruments for this demand in stroke
patients [2,3]. Although haemorrhage can easily be iden-
tified on the perfusion imaging source data we decided to
perform a conventional T2* weighted sequence due to
advantages in spatial resolution and a limited extend of
skull base artefacts at 3T.
Diffusion weighted imaging (DWI) is widely accepted as
sensitive to the actual size of infarction at the moment of
examination, while it underestimates the final size [20].
Recently evidence emerged, that approximately 1/3 of
DWI lesions are normalizing to a certain degree if they
were diagnosed in a 3 h time window [21,22]. This revers-
ibility seems to depend on delay of imaging, reperfusion
and localization of the infarct [23]. However, according to
our experience, lesion regression is rare beyond a 3 hour
time window. We study all recent timeframes after ictus to
get a representative picture of DWI lesion evolution in
acute stroke. Although it has never been studied in detail
we add a day 5-7 control to validate whether reversibility
was permanent or transient.
Several studies tried to evaluate the best possible modality
to raise sensitivity for final infarct size by adding perfusion
imaging to the diagnostic protocol [20,24,25]. However,
the ideal technique of PI and especially its post-processing
has not yet been established [20,24]. Several publications
found differing results about PI lesion prediction depend-
ing on different processing methods [24]. Yamada and co-
workers found the highest sensitivity for MTT maps. They
showed sensitivity for final infarct volume of 85-94%
based on MTT, generated from data based on 12 patients
with persistent vessel occlusion. This high sensitivity was
associated with a positive predictive value of 54-61% [20].
In contrast, Parsons et al. found rCBF most accurately pre-
dicts infarct growth in mismatch patients [25]. EPITHET
and DEFUSE both used non-delay-corrected Tmax
approaches to determine perfusion deficit [14,15]. The
potential limitation of a Tmax approach is its sensitivity to
chronic perfusion deficits. Depending on the presence
and diameter of communicating arteries of the circle of
Willis perfusion compensation can vary. We decided to
use MTT maps after sSVD (standard singular value decom-
position) and bSVD (block-circulant SVD) deconvolu-
tion. Therefore, we will be able to compare a non-delay-
corrected (sSVD) to a delay-corrected (bSVD) approach.
Furthermore we add vessel occlusion as an additional
parameter to evaluate the mismatch model. Neither
DEFUSE nor EPITHET took the target in account for the
question of superior prediction of final infarct size. There-
fore, we integrated a time-of-flight (TOF) MR angiography
into our protocol to assess vessel status. TOF-MRA has
been used in several trials before [4,5,10,12]. It is a robust
non-invasive tool to determine the vessel-status in acute
stroke patients with a sensitivity of 84.2% and a specificity
of 84.6% compared to conventional angiograms [26].
FLAIR was included to assess the final size of the infarc-
tion on day 5-7. Furthermore FLAIR helps to evaluate the
age of the stroke and to diagnose white matter lesions.
With those five sequences a maximum of necessary infor-
mation can be obtained with minimal time consumption.
Possible Consequences
The aim of this study is to describe the incidence of mis-
match and the predictive value of PI for final lesion size
and functional outcome depending on door-to-imaging
Table 2: Comparative synopsis of the 1000Plus, EPITHET and DEFUSE projects
1000Plus DEFUSE EPITHET
Time Window (onset-imaging) 0-24 hours 0-6 hours receiving alteplase 3-6 hours receiving alteplase
Imaging for Patient selection MRI CT CT
Patients (to be) included 1200 74 101
PI post-processing MTT maps with and without delay 
correction
Tmax 
(time to peak without delay 
correction)
Tmax 
(time to peak without delay 
correction)Page 6 of 8
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ize PI for future randomized clinical trials as for individ-
ual therapeutic decisions. We expect to make a significant
contribution to this challenging task with "1000Plus".
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